Table 2.
Mutations in ISWI components reported in TCGA publications.
| Gene | Cancer type | Data source | No. of mutations | No. of total | % of mutations |
|---|---|---|---|---|---|
| BAZ1A (ACF1) | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 5 | 72 | 6.9% |
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 1 | 25 | 4.0% | |
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 12 | 286 | 4.2% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 13 | 250 | 5.2% | |
| BAZ1B (WSTF) | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 4 | 71 | 5.6% |
| Lung | Small Cell Lung Cancer (Johns Hopkins, Nature Genetics 2012) | 3 | 42 | 7.1% | |
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 1 | 25 | 4.0% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 13 | 250 | 5.2% | |
| BAZ2A (TIP5) | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 4 | 71 | 5.6% |
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 1 | 25 | 4.0% | |
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 15 | 288 | 5.2% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 16 | 246 | 6.5% | |
| CECR2 | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 4 | 71 | 5.6% |
| Lung | Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 8 | 178 | 4.5% | |
| Melanoma | Cutaneous Melanoma (Broad, Cell 2012) | 11 | 121 | 9.1% | |
| Melanoma (Broad/Dana Farber, Nature 2012) | 4 | 25 | 16.0% | ||
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 17 | 288 | 5.9% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 14 | 250 | 5.6% | |
| RBBP4 (RbAP48) | Lung | Small Cell Lung Cancer (Johns Hopkins, Nature Genetics 2012) | 2 | 42 | 4.8% |
| Prostate | Prostate Adenocarcinoma, Metastatic (Michigan, Nature 2012) | 3 | 61 | 4.9% | |
| RBBP7 (RbAP46) | Cholangiocarcinoma | Cholangiocarcinoma (National University of Singapore,Nature Genetics 2012) | 1 | 8 | 12.5% |
| RSF1 | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 3 | 71 | 4.2% |
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | |
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 17 | 288 | 5.9% | |
| Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 1 | 22 | 4.5% | ||
| SMARCA5 (ISWI, SNF2H) | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 4 | 71 | 5.6% |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 13 | 250 | 5.2% | |
| SMARCA1 (SNF2L) | Cholangiocarcinoma | Cholangiocarcinoma (National University of Singapore,Nature Genetics 2012) | 1 | 8 | 12.5% |
| Colorectal | Colorectal Adenocarcinoma (TCGA, Nature 2012) | 9 | 225 | 4.0% | |
| Stomach | Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 1 | 22 | 4.5% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 18 | 247 | 7.3% | |
| BPTF (NURF) | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 8 | 129 | 6.2% |
| Cholangiocarcinoma | Cholangiocarcinoma (National Cancer Centre of Singapore, Nature Genetics 2013) | 1 | 15 | 6.7% | |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 5 | 72 | 6.9% | |
| Lung | Lung Adenocarcinoma (Broad, Cell 2012) | 8 | 182 | 4.4% | |
| Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 12 | 179 | 6.7% | ||
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | |
| Cutaneous Melanoma (Broad, Cell 2012) | 9 | 122 | 7.4% | ||
| Cutaneous Melanoma (Yale, Nature Genetics 2012) | 5 | 91 | 5.5% | ||
| Stomach | Stomach Adenocarcinoma (Pfizer and UHK, Nature Genetics 2014) | 5 | 100 | 5.0% | |
| Stomach Adenocarcinoma (TCGA, Nature 2014) | 18 | 290 | 6.2% | ||
| Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 1 | 22 | 4.5% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 20 | 247 | 8.1% |
Data from cell lines or single case reports were not included in the table. Mutation rates of less 4% are not presented.